AXL and non-small cell lung carcinoma: In addition, other studies have combined AXL inhibitors, which inhibit dendritic cells, increase the number of TCF1+ CD8+ T cells in the tumour microenvironment and restore the PD‐1 blockade sensitivity of STING‐inhibited LKB1‐mutant NSCLC [41].